This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10: C93 | C93.0 Acute monoblastic/monocytic leukemia | C93.1 Chronic myelomonocytic leukemia (CMML) | C93.2 Atypical chronic monocytic leukemia | C93.3 Juvenile myelomonocytic leukemia (JMML) | C93.9 Monocytic leukemia, unspecified | Special Copayment Reduction V193 (copayment 5%, for 5 years from the registration date) |
| B. Synonyms | Acute monocytic leukemia (AMoL), acute monoblastic leukemia (AMoL M5), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), Naegeli-type monocytic leukemia |
| C. Adult onset | Very high — CMML occurs mainly in older adults, with a median age at diagnosis of 73; acute monocytic leukemia (AML-M5) accounts for 15-20% of adult AML; JMML is a very rare disease occurring in children aged 4 or younger |
| Contents | 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References |
Monocytic leukemia began to be recognized as a distinct clinical entity in the early 20th century with advances in morphologic hematologic classification. In 1913, Löber described cases of monocyte-predominant leukemia, and in 1938, Naegeli morphologically defined monoblastic leukemia (monocytoblastic leukemia). Later, in 1953, Schilling classified the mature monocyte-predominant type, and a dichotomy distinguishing the 'Schilling type' and the 'Naegeli type' came into use.
In 1976, the FAB (French-American-British) classification was introduced, subdividing acute monoblastic leukemia (M5a) and acute monocytic leukemia (M5b); this classification was later integrated into the WHO classification as subtypes of AML including monocytic differentiation.
Chronic myelomonocytic leukemia (CMML) holds a unique position, showing both myelodysplastic and myeloproliferative features, and its classification was long controversial. It was initially classified as MDS in the FAB classification, then reclassified into the overlapping MDS/MPN category in the 2001 WHO classification and recognized as an independent disease group. Juvenile myelomonocytic leukemia (JMML) was first described as an independent clinical entity by Raao in 1974 and was included in the MDS/MPN category in the 2001 WHO classification. The central role of RAS pathway gene mutations in JMML was gradually elucidated in the 1990s-2000s.
The causes of acute monocytic leukemia (AML-M5) are similar to those of AML in general. Prior cytotoxic chemotherapy (especially topoisomerase II inhibitors: etoposide, doxorubicin) is a risk factor for monocytic AML with 11q23 KMT2A (MLL) rearrangement. Radiation therapy and benzene exposure are also associated risk factors. Secondary AML arising from prior MDS or MPN may also progress with monocytic differentiation.
The causes of CMML are mainly intrinsic (genetic) factors, and few exogenous risk factors have been established. Aging is the most important risk factor, with peak incidence in the 70s-80s. Prior chemoradiotherapy, especially exposure to alkylating agents, can cause therapy-related CMML. TET2, SRSF2, and ASXL1 mutations in clonal hematopoiesis are known to act as a precursor stage of CMML.
JMML occurs in children under 5 years of age, and germline or somatic mutations in genes that activate the RAS pathway are the key cause. Neurofibromatosis type 1 (germline NF1 gene mutation) increases the risk of JMML 200-500-fold, and JMML can also occur in children with Noonan syndrome (germline PTPN11 mutation). In about 90% of JMML cases, mutually exclusive mutations are found in one of the RAS pathway genes (PTPN11, KRAS, NRAS, NF1, CBL).
The most characteristic genomic abnormality in acute monocytic/monoblastic leukemia is KMT2A (MLL) 11q23 rearrangement. t(9;11)(p22;q23) KMT2A-MLLT3 is the most common and is classified as intermediate risk under ELN 2022. Other KMT2A partners (t(6;11), t(10;11), t(11;19), etc.) are mostly adverse risk. Monocytic differentiation is also common in NUP98-rearranged AML (NUP98-NSD1, NUP98-HOXA9, etc.).
Genomic abnormalities in CMML: somatic mutations are found in >90% of CMML patients. Key genes:
Karyotypic abnormalities occur in 30% of CMML, and monosomy 7 (-7), trisomy 8 (+8), and complex karyotype are poor prognostic factors. JMML genomics: somatic PTPN11 mutation (35%), germline PTPN11 mutation/Noonan syndrome (15%), KRAS mutation (15%), NRAS mutation (20%), germline NF1 loss (11%), germline CBL mutation (10-15%). The degree of DNA hypermethylation (methylation cluster) is strongly associated with JMML prognosis and is used to predict the risk of relapse after transplantation.
Monocytic leukemia is a heterogeneous group that accounts for a relatively small proportion of all leukemias. Acute monocytic/monoblastic leukemia (AML-M5) accounts for about 15-20% of all AML and occurs in both children and adults, but the rate of KMT2A rearrangement is higher in children (especially infants).
CMML is a relatively rare disease, with a worldwide incidence of about 0.3-1.0 per 100,000 population. The median age at diagnosis is 73, with occurrence concentrated in older adults, and it is 1.5-2 times more common in men. In Korea, the number of CMML patients is estimated at about 100-200 per year, accounting for about 20-30% of all MDS/MPN patients. In Health Insurance Review & Assessment Service (HIRA) data, the frequency of CMML among older patients shows a continuing upward trend.
JMML is a very rare pediatric disease with an annual incidence of about 1-2 per 1,000,000 children. The median age at diagnosis is about 2 years, and it is twice as common in boys. The incidence in children with NF1 is several hundred times higher than in the general population, and 'Noonan-associated JMML', which spontaneously resolves transiently, is characteristic in children with Noonan syndrome. In Korea, JMML is an ultra-rare disease with an estimated 10 or so new cases per year.
The key mechanism of acute monocytic leukemia is aberrant activation of the monocytic differentiation pathway. In the normal process of differentiation from common myeloid progenitors (CMP) through granulocyte-monocyte progenitors (GMP) to monocytes, KMT2A (MLL) fusion proteins aberrantly activate the HOX gene cluster, blocking differentiation and inducing unlimited self-renewal. KMT2A fusions promote histone H3K4 methylation, locking in a specific epigenetic state, and cause sustained expression of developmental transcription factors such as HOXA9, HOXA10, and MEIS1.
Pathophysiology of CMML: a multistep process that begins with clonal hematopoiesis. TET2 mutation (founding clone) → additional SRSF2 or RAS mutation (clonal expansion) → monocytic differentiation bias (SRSF2 mutation selectively promotes proliferation of monocytic progenitors) → monocytic hyperproliferation in the bone marrow and organ infiltration. GM-CSF (granulocyte-macrophage colony-stimulating factor) hypersensitivity plays an important role in the pathophysiology of CMML. RAS mutations constitutively activate the RAS-MAPK pathway and mediate GM-CSF hypersensitivity.
Pathophysiology of JMML: mutations in RAS pathway genes (PTPN11, KRAS, NRAS, NF1, CBL) constitutively activate the RAS-MAPK pathway, causing GM-CSF hypersensitivity. As a result, the ability of monocytic progenitors to proliferate even without GM-CSF (cytokine hypersensitivity) is the core pathophysiology of JMML and is also used as a diagnostic marker (GM-CSF hypersensitivity CFU assay). DNA hypermethylation is involved in JMML progression, and prognostic stratification is possible by methylation profile.
Acute monocytic/monoblastic leukemia is characterized by general AML symptoms (fatigue, pallor, bleeding, infection) along with tissue infiltration symptoms specific to monocytic differentiation. Gingival hyperplasia is the most characteristic finding of AML-M5 and results from infiltration of gingival tissue by monocytes and monoblasts. Leukemia cutis: monoblasts infiltrate the dermis, producing purple-brown papules and nodules. CNS involvement is more common than in other AML subtypes, and headache, cranial nerve palsy, and signs of meningeal irritation may occur. Hepatomegaly, splenomegaly, and lymphadenopathy are common.
CMML symptoms: a slowly progressive chronic course, initially dominated by mild fatigue, sweating, and weight loss. Left upper quadrant discomfort and early satiety due to splenomegaly, and rarely acute left upper quadrant pain due to splenic infarction. Skin lesions (monocytic skin infiltration) and serous effusions (pleural effusion, ascites, pericardial effusion) may occur. Autoimmune phenomena (vasculitis, skin rash, arthralgia) accompany 15-20% of cases.
JMML symptoms: mainly in children aged 4 or younger, fever, skin rash, lymphadenopathy, splenomegaly and hepatomegaly, and cough occur. Facial findings (rash, preauricular lymphadenopathy) are common, and weight loss and failure to thrive accompany them.
Signs of acute monocytic leukemia: on blood tests, leukocytosis (numerous monoblasts), marked elevation of LDH and uric acid, and elevated serum lysozyme (released by monocyte degranulation). Elevated serum lysozyme is a biochemical marker of monocytic differentiation and can cause renal tubular injury leading to hypokalemia. Coagulopathy is frequent, and DIC may accompany it, though milder than in APL. Bone marrow examination shows increased blasts with predominance of monoblasts or mature monocytes. Flow cytometry confirms a monocytic-lineage immunophenotype of CD14+/CD64+/CD11b+/CD34±.
Signs of CMML: an absolute monocyte count >1,000/μL in peripheral blood (persisting ≥3 months) is the key diagnostic finding. The bone marrow shows hypercellularity, monocytic proliferation, and dysplasia. On flow cytometry, a classical monocyte (CD14++/CD16−) fraction >94% is specific for the diagnosis of CMML (useful for differentiation from reactive monocytosis and other MDS/MPN). Elevated serum β2-microglobulin and LDH reflect tumor burden. Signs of JMML: increased monocytes and immature myeloid cells in peripheral blood, variable WBC (30,000-100,000/μL), and characteristically elevated HbF, fetal hemoglobin (HbF) >10% (considering age).
There is no standard population screening for monocytic leukemia. However, careful follow-up of high-risk groups is needed. High-risk groups for CMML: in older patients with confirmed clonal hematopoiesis (CHIP), especially carriers of TET2, SRSF2, or ASXL1 mutations, closely check the monocyte count on routine complete blood counts. In patients previously diagnosed with MDS, if a trend of increasing monocytes develops, suspect transformation to CMML and perform a bone marrow examination.
Children at risk of JMML: in children with NF1 (neurofibromatosis type 1), if fever, splenomegaly, and skin rash develop at age 4 or younger, JMML should be actively suspected, and a complete blood count and referral to pediatric hematology-oncology are needed. For JMML occurring in children with Noonan syndrome, careful observation is needed first, considering the possibility of spontaneous resolution. If unexplained chronic monocytosis (>1,000/μL) persists for 3 months or longer in an adult, a bone marrow examination is needed to evaluate for CMML. Flow cytometry and NGS are useful for differentiation from reactive monocytosis (infection, autoimmune, inflammatory conditions, etc.).
Acute monocytic/monoblastic leukemia: classified in the WHO 2022 classification as AML with monocytic/monoblastic differentiation. Blasts ≥20% in the bone marrow or blood, of which monoblasts or monocytic-lineage cells are ≥80%. Immunophenotype: CD14, CD64, CD11b, CD11c, CD4 (weak), HLA-DR. Nonspecific esterase (ANAE) positivity is an auxiliary morphologic marker. Molecular tests: KMT2A FISH/NGS, NUP98 rearrangement, etc.
Diagnosis of CMML (WHO 2022):
Diagnosis of JMML: diagnosed by clinical criteria (splenomegaly, elevated HbF, presence of monoblastic precursors in PB, WBC >10,000/μL) and molecular criteria (PTPN11/KRAS/NRAS/NF1/CBL mutation, or positive GM-CSF hypersensitivity CFU culture). Confirmation of RAS pathway mutations by NGS panel is essential.
Acute monocytic/monoblastic leukemia: in line with standard AML treatment, 7+3 induction therapy is given, and when complete remission is achieved, consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation is performed. In KMT2A-rearranged AML, the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) is considered in combination for some KMT2A-rearranged subtypes. In patients with suspected CNS involvement or high-risk patients, lumbar puncture and prophylactic CNS treatment are considered.
Treatment of CMML: CMML without treatment indications (asymptomatic, low risk) is observed (watch-and-wait). When treatment indications arise: hypomethylating agents (HMA) — azacitidine or decitabine — are first-line treatment. Azacitidine has an overall response rate of about 30-40%, complete remission 5-10%, and median duration of response of about 12-18 months. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only option for cure, with 5-year survival rates of 30-40% reported in transplant-eligible patients. Venetoclax + azacitidine is also being studied in CMML, with some responses observed. Clinical studies: CEP-701 (FLT3 inhibitor), ruxolitinib (JAK1/2 inhibitor), luveltinib, etc.
Treatment of JMML: in Noonan-associated JMML (germline PTPN11), observe for 3-6 months to check for possible spontaneous resolution and treat if it progresses. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment, with 3-5-year EFS around 50%. Before transplantation, the disease is controlled with azacitidine/decitabine or low-dose cytarabine. Clinical studies of MEK inhibitors (trametinib) are under way for PTPN11/KRAS/NRAS mutations.
The prognosis of acute monocytic leukemia is determined by the accompanying cytogenetic abnormalities and molecular mutations. Among KMT2A rearrangements, t(9;11) is intermediate risk under ELN 2022 (5-year OS 40-50%), and other KMT2A partners are adverse risk (5-year OS 15-25%). Monocytic differentiation itself is not an independent prognostic factor; the accompanying genomic abnormalities determine prognosis.
Prognosis of CMML: overall median survival is 12-36 months, and prognosis worsens markedly with progression to CMML-2 or AML. Risk stratification is performed with CPSS (CMML Specific Scoring System), CPSS-Mol, or the Mayo molecular model. In high-risk CMML (increased blasts, ASXL1 mutation, adverse karyotype), median OS is only 12-18 months. After allogeneic transplantation, 5-year OS is 30-40% and the relapse rate is 35-50%. Prognosis of JMML: without transplantation, median survival is 1-2 years, and 3-year EFS after transplantation is about 50%. Germline NF1 mutation, hypermethylation cluster 3, age >2 years, male sex, and thrombocytopenia at transplantation are poor prognostic factors. The rate of spontaneous resolution in Noonan-associated JMML is 20-30%.
There is no specific method of preventing monocytic leukemia, but management of risk factors is important. Monitoring after chemoradiotherapy: especially in patients who received topoisomerase II inhibitors (etoposide, doxorubicin), monitor for increased monocytes with regular complete blood counts for 1-5 years after the end of treatment. Management of carriers of clonal hematopoiesis: in patients with clonal hematopoiesis carrying SRSF2, TET2, or ASXL1 mutations, perform complete blood counts 1-2 times a year with close tracking of the monocyte count. If abnormal, early referral to a hematologist for early diagnosis of CMML.
Monitoring of children at risk of JMML: in children diagnosed with NF1, early detection of JMML is pursued through regular consultation with pediatric hematology-oncology. In children with Noonan syndrome, evaluate immediately if symptoms suspicious for JMML, such as fever or splenomegaly, develop at age 4 or younger. Genetic counseling: in families with germline PTPN11, NF1, or CBL mutations, establish early screening and monitoring plans for at-risk children through genetic counseling. Maintaining a healthy lifestyle (normal body weight, no smoking, avoiding excessive alcohol) may contribute to reducing the risk of hematologic cancers overall, including AML.